255 DNA and RNA alterations associated with colorectal peritoneal metastases: A systematic review Table 3. Continued Reference Level of Testing Name Genes, Molecules or Panel Investigated Type of Analysis Performed Gene or Molecule Name and Mutation or Expression Status (n) No. of Patients with PM (N) and Outcomes (n) No. of Patients without PM (N) and Outcomes (n) MMR Status (MSI/MSS) Findings as Reported by Authors in Studies Sjo et al. 36 DNA TP53 PCR N = 49 N = 148 N/A Univariate analyses demonstrated that PM was significantly associated with mutations in the TP53 gene (p = 0.05 f). Multivariate analyses confirmed the previous finding (OR = 2.4; 95%CI = 1.24.8, p = 0.013 g). TP53 mutant - - TP53 wild-type - - Smith et al. 37 DNA KRAS, NRAS, BRAF, and PIK3CA PS and Sequenom N = 283 N = 1667 Co-occurred with BRAF wild-type tumors BRAF mutations were more common in patients with PM-only compared to LM-only (22.2% vs. 6.7%, p = 0.00092 d), although this association with PM did not withstand correction for multiple testing. BRAF mutations were significantly associated with PM (p = 0.018), which did not remain significant after Bonferroni correction (p = 0.36). For KRAS, NRAS, and PIK3CA, there was no association found for PM. KRAS mutant 131 (/282) 693 (/1667) BRAF mutant 36 (/283) 193 (/1663) NRAS mutant 7 (/283) 62 (/1656) PIK3CA mutant 40 (/280) 293 (/1627) 11
RkJQdWJsaXNoZXIy MTk4NDMw